The Emerging Role of ctDNA in Breast Cancer

Circulating tumor DNA (ctDNA) represents a transformative, noninvasive biomarker in modern oncology. Specifically, ctDNA in breast cancer has emerged as a critical tool for detecting minimal residual disease (MRD) and monitoring treatment responses. These assays identify tumor-derived DNA fragments in the blood, often revealing molecular relapse long before conventional imaging detects overt metastasis. Consequently, clinicians are increasingly exploring how this technology can refine risk stratification and personalize patient care during and after curative-intent therapy.

Clinical Validity and Predictive Value

Research confirms that ctDNA dynamics during neoadjuvant therapy correlate strongly with pathologic complete response and long-term survival outcomes. Following surgery, the presence of ctDNA—indicative of MRD—serves as a robust predictor of future distant recurrence. Furthermore, the emergence of these biomarkers during surveillance typically precedes a clinical diagnosis of metastatic disease by several months. While these assays demonstrate high analytical and clinical validity, their ability to improve actual patient outcomes through guided management remains under investigation.

Understanding ctDNA in Breast Cancer Limitations

Despite the prognostic power of these tests, their optimal clinical utility is not yet certain. For instance, evidence demonstrating that ctDNA-guided treatment escalation or de-escalation improves survival remains limited. Additionally, the medical community has not yet established the ideal timing or frequency for testing. Most current guidelines suggest that while ctDNA provides valuable complementary data, it should not yet replace standard risk-assessment tools in routine clinical practice. Ongoing prospective trials are currently evaluating whether intervening based on ctDNA results can truly change the disease trajectory.

Future Directions in Precision Monitoring

The transition of ctDNA assays from research settings to routine care requires more robust interventional data. Clinicians must weigh the strengths and limitations of current assays while considering patient preferences and evolving evidence. Therefore, prospective interventional trials are essential to determine if molecular-guided management offers a survival benefit over standard-of-care approaches. As technology advances, these assays may eventually enable highly personalized treatment pathways, reducing both over-treatment and the risk of late recurrence.

Frequently Asked Questions

What is the primary benefit of ctDNA testing in early breast cancer?

The main advantage is the early detection of minimal residual disease (MRD), which allows for the identification of potential recurrence much earlier than traditional imaging or clinical exams.

Can ctDNA results be used to change current treatment plans?

While ctDNA provides significant prognostic information, its use in guiding treatment changes is still considered investigational. Most experts recommend waiting for results from ongoing clinical trials before making routine treatment adjustments based solely on ctDNA status.

How does ctDNA help during neoadjuvant therapy?

Changes in ctDNA levels during neoadjuvant treatment can indicate how well a tumor is responding to therapy, helping to predict the likelihood of achieving a pathologic complete response (pCR).

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Schlam I et al. Circulating Tumor DNA in Early Breast Cancer: A Review. JAMA Oncol. 2026 May 28. doi: 10.1001/jamaoncol.2026.1465. PMID: 42207534.

2. Liu M et al. Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review. PMC. 2025 Aug 27. PMCID: PMC11345678.

3. Parsons H et al. ctDNA in Early-Stage Breast Cancer: Prognostic Power vs Clinical Actionability. OncLive. 2026 March 06.